Show simple item record

dc.contributor.authorGonzalez-Ortiz, Fernando
dc.contributor.authorKarikari, Thomas K.
dc.contributor.authorVruchte, Danielle Taylor-Te
dc.contributor.authorShepherd, Dawn
dc.contributor.authorKirsebom, Bjørn-Eivind Seljelid
dc.contributor.authorFladby, Tormod
dc.contributor.authorPlatt, Frances
dc.contributor.authorBlennow, Kaj
dc.date.accessioned2024-12-03T08:51:00Z
dc.date.available2024-12-03T08:51:00Z
dc.date.issued2024-10-25
dc.description.abstractNiemann–Pick disease type C and Alzheimer’s disease are distinct neurodegenerative disorders that share the presence of neurofibrillary tangle pathology. In this multicentre study, we measured plasma phosphorylated-tau217 in controls (n = 60), Niemann–Pick disease type C (n = 71) and Alzheimer’s disease (n = 30 positive for amyloid and negative for tau in CSF [A+ T−] and n = 30 positive for both [A+ T+ ]). Annual Severity Increment Score and Lysotracker measurements were evaluated in the Niemann–Pick disease type C group to estimate the rate of progression and lysosomal enlargement, respectively. In the cross-sectional analysis, plasma phosphory lated-tau217 was increased in Niemann–Pick disease type C compared with controls (2.52 ± 1.93 versus 1.02 ± 0.34 pg/mL, respectively, P < 0.001) and inversely correlated with age at disease onset (R = −0.54, P < 0.001). In the longitudinal analysis, plasma phosphorylated-tau217 was associated with disease progression determined by Annual Severity Increment Score (R = 0.48, P < 0.001) and lysosomal enlargement (R = 0.26, P = 0.004). We found no differences between A+ T− Alzheimer’s disease and Niemann–Pick disease type C (2.67 ± 1.18 versus 2.52 ± 1. 93 pg/mL, P = 0.31); however, A+ T+ Alzheimer’s disease had significantly higher levels than Niemann–Pick disease type C (3.26 ± 1.36 versus 2.52 ± 1.93 pg/mL, P = 0.001). Our findings suggest that plasma p-tau217 can increase in brain disorders with isolated tau pathology. Plasma p-tau217 associations with disease progression and severity make it a potential marker in Niemann–Pick disease type C.en_US
dc.identifier.citationGonzalez-Ortiz, Karikari, Vruchte, Shepherd, Kirsebom, Fladby, Platt, Blennow. Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C. Brain Communications. 2024;6(6)en_US
dc.identifier.cristinIDFRIDAID 2323305
dc.identifier.doi10.1093/braincomms/fcae375
dc.identifier.issn2632-1297
dc.identifier.urihttps://hdl.handle.net/10037/35880
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.relation.journalBrain Communications
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2024 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titlePlasma phosphorylated-tau217 is increased in Niemann–Pick disease type Cen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)